Anti-Mouse Dendritic Cells – Purified in vivo GOLD™ Functional Grade
Anti-Mouse Dendritic Cells – Purified in vivo GOLD™ Functional Grade
Product No.: D112
Clone 33D1 Target Dendritic Cells Formats AvailableView All Product Type Monoclonal Antibody Alternate Names DC Marker, 33D1, DCIR2 (dendritic cell inhibitory receptor 2) Isotype Rat IgG2b κ Applications in vivo , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Immunogen Dendritic cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737490 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 33D1 recognizes mouse DCIR2. Background Dendritic cells are antigen presenting cells that have two functions. They scan the body collecting and processing antigen material that they present on the cell surface to T cells, and they maintain T cell tolerance to “self”. The morphology of dendritic cells is characterized by an extremely large surface-to-volume ratio. Murine splenic dendritic cells can occur in two types: myeloid (cDC) and lymphoid (pDC). Lymphoid dendritic cells produce high amounts of IFN-α and are also called Plasmacytoid dendritic cell because they have an appearance similar to plasma cells. Myeloid, or conventional dendritic cells, secrete IL-12, IL-6, TNF, and chemokines and can be further categorized into three subtypes (CD4−CD8+, CD4+CD8− and CD4−CD8−). These differ from other migratory dendritic cells such as Langerhans cells and interstitial dendritic cells that migrate from peripheral tissues to the lymph nodes. The exact nature and biological activity of the dendritic cell surface marker DCIR2 is currently unknown. DCs are known to play a role in several diseases including myeloid cancer, pDC leukemia, HIV, lupus erythematosus, Crohn's disease and ulcerative colitis. However, it is thought that DCs may be able to control cancer progression because increased densities of DC populations have been linked with better clinical outcome. Lung cancers have been found to include four different subsets of dendritic cells; some of which can activate immune cells that can suppress tumor growth. Dendritic cells have also been shown to play a role in the success of cancer immunotherapies in experimental models. Specifically, the immune checkpoint blocker anti-PD-1 has been shown to indirectly activate DCs through IFN-γ released from drug-activated T cells. Agonizing the non-canonical NF-κB pathway also activates DCs and further enhances anti-PD-1 therapy in an IL-12-dependent manner. Antigen Distribution Murine DCIR2 is found on dendritic cells of the thymus, spleen, lymph nodes, and Peyer’s patches. DCs in the bone marrow may express DCIR2 in the presence of GM-CSF. However, this expression is notably downregulated when IL-4 is present. Furthermore, DCIR2 has been found In vivo on brain dendritic cells post infection with T. gondii. Function GM-CSF is reported to increase expression of 33D1 antigen on dendritic cells from bone marrow cells and IL-4 reported to down regulate the 33D1 antigen. PubMed UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 33D1, a monoclonal antibody targeting the dendritic cell marker DCIR2 (also known as C-type lectin domain family 4, member a4 or Clec4a4), is commonly used in vivo in mouse models for several applications:
Overall, clone 33D1 provides a powerful tool for dissecting the complex roles of dendritic cells in the immune system, offering insights into their functions and potential therapeutic targets. In the literature, several antibodies and proteins are commonly used alongside 33D1, which targets dendritic cells, particularly conventional type 2 dendritic cells (cDC2). Here are some of these commonly used antibodies and proteins:
These antibodies help in defining the specific type of dendritic cells and excluding other cell types, which is crucial for studying dendritic cell functions and their role in immune responses. The combination of these markers provides a comprehensive view of the dendritic cell population in various tissues and experimental conditions. The key findings from scientific literature using clone 33D1 citations are:
These findings establish clone 33D1 as an essential tool for immunological studies focused on dendritic cell biology, immune regulation, and related disease mechanisms. Dosing regimens for clone 33D1 (anti-mouse DCIR2 antibody) vary depending on the mouse model and experimental goal, but several established protocols provide guidance:
Model-specific considerations:
Summary Table: 33D1 Dosing Regimens in Mouse Models
Key points:
If you need dosing protocols for a specific mouse strain or unique disease model, please specify, as some regimens may require further adjustment. References & CitationsSteinman, R. M. et al. (1982) Pro. Natl. Acad. Sci. USA 79:161
Steinman, R. M. et al. (1983) J. Exp. Med. 157:613
Nussenzweig et al. 1982. Proc Natl Acad Sci U S A. 79(1):161-5. PMID: 6948298.
Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-1034 | |
C247 | |
F1175 | |
R1214 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
D382 | |
D384 | |
D104 | |
D105 | |
D106 | |
D376 | |
D377 | |
D378 | |
D380 | |
D112 | |
D212 |
